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Abstract
Background: Rotavirus infection and its associated hospitalization of  children less than 5 years old in middle- and low-income 
countries remains a public health challenge. We hypothesized that the Rotarix®potency is affected by non-optimal temperatures 
which translates into reduced vaccine effectiveness in these settings.
Objective: To assess the effect of  non-optimal temperatures on the potency of  the Rotarix® vaccine in South Africa.
Methods: Rotarix® vaccine was exposed to temperatures reflecting breaches in the cold chain. Vero cells (ATCC CCL-81) 
grown in a 24-well tissue culture plates were infected with Rotarix® vaccine viruses after exposure to non-optimal temperatures 
and the potency of  the vaccine was determined using the plaque assay. 
Results: Exposure of  the Rotarix® vaccine to seasonal temperatures in KwaZulu-Natal for 6 hours and to extreme tempera-
tures of  40oC for 72 hours as well as to -20oC and -80oC for 12 hours did not affect the potency of  the vaccine beyond its ex-
pected standard of  >7 x 105 PFU/ml.
Conclusion: This study revealed that the Rotarix® vaccine remains potent even after exposure to non-optimal temperatures. 
However, this study only explored the effect of  a constant ‘adverse’ temperature on vaccine potency and not the effect of  tem-
perature fluctuations.
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Introduction
Based on data emanating from studies on the role of  ro-
tavirus in the burden of  disease1,2 and local safety and 
efficacy trials of  the rotavirus vaccine3, South Africa de-
cided as the first African country to include the monova-
lent rotavirus vaccine (Rotarix®, GlaxoSmithKline Bio-
logicals, Rixensart, Belguim) in its national immunization 
programme, starting in 20084. The vaccination consists 
of  two-doses, administered orally at 6 and 14 weeks of  
age, simultaneously with other vaccines included in the 
expanded programme on immunization (EPI). The vac-
cine coverage increased rapidly since 2009 and by 2010, 
about 67% of  children under a year old had received a 
complete schedule of  Rotarix® immunization. The vac-
cine coverage rate has since increased to more than 90% 
in some provinces5. However, rotavirus prevalence and 
its associated hospitalization inSouth Africa including 
KwaZulu-Natal (KZN) province6 has raised questions re-
garding the effectiveness of  this vaccine.  To ensure that 
children receive potent and effective vaccines, the vaccine 
has to be stored at the optimum temperatures while in 
storage and on transit. However, accidental or inevitable 
exposure of  this vaccine to heat or freezing temperature 
while in storage or in transit can result in loss of  potency 
as reported previously by Matthias et al7. The possibili-
ty of  vaccine exposure to non-optimal temperatures was 
considered as a factor responsible for the reduced effec-
tiveness of  the rotavirus vaccine in middle- and low-in-
come countries. These countries are often characterized 
by poor road networks and inadequate electricity supply. 
Poor road networks can expose vaccines to non-optimal 
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temperatures in transit while inadequate electricity supply 
can also expose the vaccines to temperature fluctuations 
during storage.
The World Health Organization (WHO) recommended 
that all vaccines except that for oral polio be kept at 2 
to 8oC during in-country distribution8. However, a poor-
ly maintained cold chain system may expose vaccines to 
non-optimal temperatures ranging from hot to freez-
ing. Rotavirus vaccine is listed as being affected by cold 
chain failure8–12. Vaccine cold-chain challenges are more 
frequently seen in low income countries in comparison 
to high income countries. Consequently, loss of  potency 
may be responsible for the reduced effectiveness of  the 
rotavirus vaccine observed in middle- and low-income 
countries. We assessed the effect of  non-optimal storage 
temperature on the potency of  the monovalent rotavirus 
vaccine.
Methods
The effect of  temperature on the potency of  the Rotar-
ix® vaccine was studied. The vaccine was obtained from 
the central pharmaceutical store of  the KwaZulu-Natal 
Department of  Health (DOH). Vaccines were exposed 
to the average temperatures experienced over the differ-
ent seasons in KwaZulu-Natal province. The potency 
was evaluated at 0, 1, 2, 3, 4, 5 and 6 hours. The average 
seasonal temperatures during 2005 till 2015 were 24oC in 
spring, 27.3oC in summer, 25.7oC in autumn and 23.3oC 
in winter13. The vaccines were also exposed to tempera-
tures of  -20oC and -80oC for 12 hours and to 40oC for 
up to 72 hours. A digital oven and freezers were used to 
simulate vaccine exposure to heat and freezing tempera-
tures respectively. The potency of  vaccines stored at the 
advised temperature of  2 to 8oC was used as the reference 
standard.  
To quantify the vaccine virus after exposure to the differ-
ent temperatures, the plaque assay described by Smith et 
al14, was used with some modifications. Vero cells (ATCC 
CCL-81) were seeded in wells of  a 24-well tissue culture 
plate at a density of  1 x 106 cells/ml in a volume of  500µl. 
The culture medium used was Eagle’s minimum essential 
medium (EMEM) supplemented with 1% HEPES, 1% 
L-glutamate and 10% heat-inactivated fetal bovine serum 
(FBS). The plates were incubated at 37oC in 5% CO2 till 
confluent. The vaccine reference standard and test sam-
ples were diluted 1:10 in trypsin/PBS (1:60) and a 1:10 
dilution in PBS without trypsin. Eight ten-fold serial dilu-
tions (10-1 to 10-8) were made of  each of  the trypsinized 
test samples in EMEM with HEPES and L-glutamate. 
The dilutions were vortexed for 15 seconds and incubat-
ed at room temperature (25oC) for 30 minutes prior to 
infection. 
The culture media was aspirated from the confluent Vero 
cell monolayer and the cells were washed twice with warm 
PBS. Vaccine virus infection was performed by inoculat-
ing 200µl of  each sample into the wells in triplicate. The 
plates were then placed in a 37oC incubator with 5% CO2 
for 1 hour. The media was replaced with an agar over-
lay which contains 1ml of  0.1 % agarosein EMEM with 
2% FBS and 1% glutamate. The agarose was allowed to 
solidify for 15 minutes at room temperature after which 
the plates were transferred to a 37oC incubator with 5% 
CO2 until plaques were formed. When plaques became 
visible, the monolayers were fixed by dispensing 1ml of  
3.6% formalin on the agar overlay followed by incubation 
at room temperature for 1 hour. Thereafter, the forma-
lin and agarose were discarded under running water. The 
monolayers were stained for 3 minutes with crystal vio-
let, washed with running water and air dried. The plaques 
were counted under an inverted light microscope (Olym-
pus, Tokyo, Japan) at 400x magnification [Figure 1 (a)and 
(b)]. The concentration of  the initial viral suspension in 
plaque forming unit per milliliter (PFU/ml) was calculat-
ed as: PFU/ml = number of  plaques x dilution factor x 
volume of  inoculum per plate.  
According to the manufacturer of  the Rotarix® vaccine, 
the vaccine is potent when it is greater than or equal to 
106 of  50% cell culture infective dose (Potency >106 
CCID50). To convert the CCID50 to plaque forming unit 
per milliliter (PFU/ml), we applied the Poisson distribu-
tion (P(k) = e-m x m k/k) and in summary PFU/ml = 0.7 
x CCID50. Therefore, 106 CCID50 = 0.7 x 106 PFU/ml 
= 7 x 105 PFU/ml. Therefore, the vaccine should have a 
minimum potency >7 x 105 PFU/ml. 
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We compared the potency of  each of  the vaccines ex-
posed todifferent temperatures to that of  our reference 
standard and to the acceptable potency according to the 
vaccine manufacturer.
Results
On receipt of  the vaccine from the central pharmacy 
store, the potency ranged between 5.2– 6.8 x 1010 PFU/
ml with an average of  5.8 x 1010 PFU/ml, represented by 
the horizontal line in figure 2 and 3. The potency of  the 
vaccines after exposure to the average seasonal tempera-
tures in KZN is shown in figure 2. At all temperatures the 
values obtained were above the minimum potency of  7 x 
105 PFU/ml as per manufacturer’s guidelines. However, 
these temperatures seem to have an effecton the vaccine 
potency as most of  the values were less than pre-exposure 
to the seasonal temperatures except those exposed to the 
average temperature of  the autumn season. Exposure to 
extreme temperatures of  40oC for 3 to 72 hours (Figure 
3) did not decrease the potency of  the vaccine below the 
minimum advised value. However, we observed a gradual 
reduction in potency as the duration of  exposure increas-
es. The vaccine potencies after exposure to -20oC and 
-80oC for 12 hours was 3.5 x 1010 PFU/ml and 3.0 x 1010 
PFU/ml respectively. Although these potencies were less 
than the potency of  the optimally stored vaccines, it was 
higher than the manufacturer’s minimum advised value.
 
                         Figure 1 (a) 
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 Figure 1 (b) 
 
Figure 2 
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 Figure 3 
Discussion 
The possibility of  the Rotarix®vaccine exposure to 
non-optimal temperatures was considered as a factor re-
sponsible for the reduced effectiveness of  this rotavirus 
vaccine in low income countries. This vaccine remained 
potent after exposure to the seasonal temperatures for 6 
hours. Although the potencies at the different seasonal 
temperatures were lower than the pre-exposure potency 
except at autumn temperature at some of  the time points. 
The observed higher potency at the 1, 4 and 5 hour time 
point of  this temperature in comparison to the pre-ex-
posed vaccine potency may be explained by a higher quan-
tity of  vaccine virus in the vials used at these time points. 
In addition, exposure to +40oC for 72 hours as well as to 
-20oC and -80oC for 12 hours was well tolerated. These 
findings correlate with a similar finding in India where a 
recently licensed thermostable live attenuated Rotavirus 
vaccine (ROTASIIL®) was found to withstand tempera-
tures as high as 40oC and 55oC for long- and short-term 
exposure respectively15. In addition, the study reported 
that the vaccine was able to tolerate a temperature shock 
of  being thawed from -20oC to a temperature of  42oC15.
The mechanism for the reduced effectiveness of  the Ro-
tarix® vaccine in middle and low income countries16 in 
contrast to the observed high effectiveness of  this vaccine 
in high income countries17 is not completely understood.
Although possible factors driving these variations in vac-
cine effectiveness have previously been reported18. Viral, 
environmental and host factors were identified as possible 
determinant of  protection elicited by this vaccine18. Pro-
tection from diverse rotavirus strains including non-vac-
cine genotypes has been reported as a significant charac-
teristic of  this vaccine16,19. However, the mechanism of  
this vaccine protection against diverse and emerging ro-
tavirus strain is incompletely understood. Environmental 
enteropathy, a sub-clinical condition affecting the small 
intestine of  children in low income countries was sug-
gested as a factor influencingvaccine effectiveness20. This 
condition is characterized by chronic exposure to faecal 
pathogens due to poor sanitation leading to chronic in-
flammation of  the intestine21. The presence of  maternal 
antibodies acquired via breast milk has been reported to 
compromise the effectiveness of  the rotavirus vaccine in 
children22. In addition, pre-existing serum immunoglobu-
lin G (IgG) was reported to have an inhibitory effect on 
the immunogenicity of  the rotavirus vaccine23.
Limitation of  the study
This study was unable to elucidate reason(s) for the main-
tained potency of  the Rotarix® vaccine after exposure 
to non-optimal temperatures. In addition, this study only 
explored the effect of  a constant ‘adverse’ temperature 
on vaccine potency and not the effect of  temperature 
fluctuations.
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Conclusion
The stability of  theRotarix® vaccine after exposure to 
diverse temperatures reflecting potential storageor tran-
sit temperatures in some middle- and low-income coun-
tries was highlighted in this study. It will be interesting to 
evaluate the effect of  non-optimal temperatures on the 
vaccine when exposed for a longer period above the time 
point in our study. Further exploration is needed to draw 
a firm conclusion on the stability of  the Rotarix® vaccine 
post exposure to more non-optimal temperatures. This 
is the only independent study on thermostability of  the 
monovalent Rotarix® vaccine. 
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